Cellular Biomedicine Group, Inc.

Form 4

January 21, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: 2005
Estimated average burden hours per response... 0.5

OMB APPROVAL

3235-0287

January 31,

OMB

Number:

Section 16. Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Chan Andrew K	2. Issuer Name and Ticker or Trading Symbol Cellular Biomedicine Group, Inc. [CBMG]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) (First) (Middle) 19925 STEVENS CREEK BLVD., SUITE 100	3. Date of Earliest Transaction (Month/Day/Year) 01/19/2016	Director 10% Owner Officer (give title below) X Other (specify below) SVP Corp Bus Dev		
(Street) CUPERTINO, CA 95014	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

(City)	(State) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)		Beneficially (D) or I Owned Indirect (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Stock	01/19/2016		M	1,516	A	\$ 5.61	147,273 <u>(2)</u>	D	
Common Stock	01/19/2016		S <u>(1)</u>	1,516	D	\$ 12.07	145,757 (2)	D	
Common Stock	01/21/2016		M	1,296	A	\$ 3	147,053 (2)	D	
Common Stock	01/21/2016		S <u>(1)</u>	1,296	D	\$ 13.87	145,747 (2)	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	onof Derivative		of Derivative Expiration I Securities (Month/Day Acquired (A) or Disposed of (D) (Instr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Non- Qualified Stock Option (right to buy) (2013 Plan)	\$ 5.61	01/19/2016		M		1,516	(3)	05/16/2023	Common Stock	1,516	
Non- Qualified Stock Option (right to buy) (2011 Plan)	\$ 3	01/21/2016		M		1,296	<u>(4)</u>	02/20/2023	Common Stock	1,296	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Chan Andrew K 19925 STEVENS CREEK BLVD., SUITE 100				SVP Corp Bus Dev		
CUPERTINO, CA 95014				5 vi Coip Bus Bev		

Reporting Owners 2

Signatures

/s/ Andrew Chan 01/21/2016

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transaction reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2015. Accordingly, the reporting person had no discretion with regard to the timing of the transaction.
- On December 22, 2015, due to miscommunications with regard to the nature of transactions undertaken by the reporting person in September 2015, the reporting person mistakenly reported the number of shares of common stock and derivative securities of the issuer owned by him after certain transactions undertaken in December 2015. As a result, the number of outstanding securities owned by the reporting person after each transaction as reported on this form reflects corrections of the reporting errors made in December 2015.
- (3) The option vested according to the following schedule: 1/31st per month following the vesting commencement date of May 16, 2014.
- (4) The option vested according to the following schedule: 1/36th per month following the vesting commencement date of February 20, 2013. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3